Mavacamten is the first-in-class, cardiac-specific myosin inhibitor that targets myosin, a protein central to the pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). By reversibly binding to myosin molecules (myosin ATPase), Mavacamten reduces the hypercontractile state of the cardiac muscle by lowering the probability of myosin being in an active state and thereby mitigating associated adverse metabolic effects1,2 . The United State Food and Drug Administration (FDA) approved Mavacamten in April 2022, following results from the pivotal EXPLORER-HCM trial.10
Author Sub-editor: Dr Pok-Tin Tang Dr Pok-Tin Tang is an ST5 cardiology registrar in the Thames Valley deanery, currently undertaking a period of out of
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
